Bolt Biotherapeutics (BOLT) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on June 10, 2026, with voting on director elections and auditor ratification.

• Only stockholders of record as of April 22, 2026, are entitled to vote.

• The board recommends voting for both director nominees and for the ratification of PricewaterhouseCoopers LLP as auditor.

• Proxy materials are available online, and multiple voting methods are provided.

Voting matters and shareholder proposals

• Proposal 1: Elect two Class II directors (William P. Quinn and Jakob Dupont, M.D.) to serve until 2029.

• Proposal 2: Ratify PricewaterhouseCoopers LLP as independent auditor for 2026.

• Shareholder proposals for the 2027 meeting must be submitted by December 29, 2026, for inclusion in the proxy statement.

• Advance notice for other proposals or nominations is required between February 10 and March 12, 2027.

Board of directors and corporate governance

• The board consists of six directors divided into three classes, with staggered three-year terms.

• Four directors are independent under Nasdaq standards; the CEO/CFO and Dr. Dupont are not independent.

• Board leadership is separated, with an independent chair (Brian O'Callaghan) appointed in May 2024.

• Three standing committees: audit, compensation, and nominating/corporate governance, all with independent members.

• Board and committees met regularly in 2025, with all directors attending at least 75% of meetings.

• Directors and officers are indemnified to the fullest extent permitted by Delaware law.